100 Active Studies

Geographic Atrophy Clinical Trials Near You

Also searched as: retina, retinal, dry AMD, eye, vision loss clinical trials

Find 100 actively recruiting geographic atrophy research studies near you. Connect with study sites, check eligibility, and explore new treatment options.

100
Active Trials
314+
Locations
27,038
Participants Needed

Recruiting Studies

RecruitingNCT04373564

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the orga...

10 locations(Scottsdale, New Haven, Chicago)
2,076 participants
Guerbet
View Study Details
RecruitingNCT06393374

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TP...

10 locations(Mobile, Chandler, La Jolla)
1,530 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNCT05633654

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatmen...

10 locations(Birmingham, Huntsville, Glendale)
1,514 participants
Gilead Sciences
View Study Details
RecruitingNCT06841354

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sac...

10 locations(Chandler, Los Angeles, San Francisco)
1,000 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNCT06541704

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (...

10 locations(Phoenix, Phoenix, Phoenix)
975 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingNCT06764875

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

This is a Phase â…¢, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) c...

10 locations(Anchorage, Phoenix, Duarte)
840 participants
AstraZeneca
View Study Details
RecruitingNCT06731478

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus stan...

10 locations(New Haven, Skokie, Kansas City)
726 participants
Daiichi Sankyo
View Study Details
RecruitingNCT06510816

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA)

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD)....

10 locations(Scottsdale, Beverly Hills, Fullerton)
630 participants
Annexon, Inc.
View Study Details
RecruitingNCT06103864

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemot...

10 locations(Daphne, Springdale, Duarte)
625 participants
AstraZeneca
View Study Details
RecruitingNCT04368559

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen....

10 locations(Birmingham, Los Angeles, Stanford)
600 participants
Mundipharma Research Limited
View Study Details
RecruitingNCT06346392

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ ade...

10 locations(Birmingham, Mobile, Tucson)
572 participants
AstraZeneca
View Study Details
RecruitingNCT06926868

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physi...

10 locations(Hot Springs, Cerritos, Cerritos)
560 participants
Bristol-Myers Squibb
View Study Details
RecruitingNCT06532006

A Phase â…¢ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

This is a double-blind, randomized, multiregion, comparative phase â…¢ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line...

10 locations(Anaheim, Los Alamitos, Greeley)
550 participants
Shanghai Henlius Biotech
View Study Details
RecruitingNCT04557462

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203 or CLNP023A23...

10 locations(Glendale, San Diego, San Dimas)
540 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNCT06291376

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease pro...

10 locations(Alabaster, Phoenix, Los Angeles)
510 participants
Alexion Pharmaceuticals, Inc.
View Study Details
RecruitingNCT06901531

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with che...

10 locations(Iowa City, Boston, Saint Louis Park)
500 participants
Astellas Pharma Global Development, Inc.
View Study Details
RecruitingNCT06564142

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function....

10 locations(Huntsville, Phoenix, Tucson)
480 participants
Alpine Immune Sciences Inc, A Subsidiary of Vertex
View Study Details
RecruitingNCT06935357

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). This study will focus on participants who have protein in their urine ...

10 locations(Little Rock, Apple Valley, Oxnard)
454 participants
Biogen
View Study Details
RecruitingNCT06356311

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The...

10 locations(Gilbert, Los Angeles, Orlando)
450 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNCT05949593

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects...

10 locations(Phoenix, Arcadia, Beverly Hills)
429 participants
Belite Bio, Inc
View Study Details
RecruitingNCT05797610

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropa...

10 locations(Birmingham, Surprise, Tucson)
428 participants
Hoffmann-La Roche
View Study Details
RecruitingNCT04379596

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemoth...

10 locations(Santa Monica, Westwood, Baltimore)
413 participants
AstraZeneca
View Study Details
RecruitingNCT06899217

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects. The...

10 locations(Birmingham, Foley, Saraland)
400 participants
CinDome Pharma, Inc.
View Study Details
RecruitingNCT05677490

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX)...

10 locations(Birmingham, Anchorage, Anchorage)
382 participants
Alliance for Clinical Trials in Oncology
View Study Details
RecruitingNCT07043400

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line the...

10 locations(Chandler, Los Alamitos, Colorado Springs)
351 participants
BeiGene
View Study Details
RecruitingNCT06963827

A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition

Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (...

10 locations(Montgomery, Los Angeles, Lauderdale Lakes)
347 participants
Takeda
View Study Details
RecruitingNCT05621811

Different Doses of Naronapride Vs. Placebo in Gastroparesis

This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group com...

10 locations(Chula Vista, Lomita, Clearwater)
320 participants
Dr. Falk Pharma GmbH
View Study Details
RecruitingNCT06719141

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and...

10 locations(Little Rock, Palo Alto, San Francisco)
320 participants
Longboard Pharmaceuticals
View Study Details
RecruitingNCT04787042

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatme...

6 locations(Scottsdale, Denver, New Haven)
316 participants
Simcha IL-18, Inc.
View Study Details
RecruitingNCT06679855

Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial

The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the ...

10 locations(Birmingham, Orange, Palo Alto)
316 participants
NICHD Neonatal Research Network
View Study Details
RecruitingNCT05947071

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

Influenza virus is a significant pathogen in pediatric solid organ transplant (SOT) recipients. However, these individuals respond poorly to standard-dose (SD) inactivated influenza vaccine (IIV). Rec...

8 locations(Stanford, Atlanta, Chicago)
312 participants
National Institute of Allergy and Infectious Diseases (NIAID)
View Study Details
RecruitingNCT06635148

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies....

10 locations(Tucson, Fullerton, La Jolla)
311 participants
Janssen Research & Development, LLC
View Study Details
RecruitingNCT04005378

Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs

Maintaining treatment engagement is critical for first episode psychosis patients to experience gains possible with coordinated specialty care (CSC). This study is designed to identify CSC participant...

3 locations(Lauderdale Lakes, Grand Rapids, Kalamazoo)
300 participants
Northwell Health
View Study Details
RecruitingNCT06005493

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cance...

10 locations(Jacksonville, Rochester, New York)
280 participants
AstraZeneca
View Study Details
RecruitingNCT04230109

Sacituzumab Govitecan In TNBC

This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacitu...

5 locations(Boston, Boston, Boston)
260 participants
Massachusetts General Hospital
View Study Details
RecruitingNCT05066217

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole HCL (EPX-100) as adjunctive therapy in children and adult p...

4 locations(Kissimmee, Roseville, Marlboro)
260 participants
Epygenix
View Study Details
RecruitingNCT05482893

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prelimi...

10 locations(Duarte, Los Angeles, Denver)
258 participants
Phanes Therapeutics
View Study Details
RecruitingNCT05219617

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in ped...

10 locations(Palo Alto, Jacksonville, Orlando)
252 participants
SK Life Science, Inc.
View Study Details
RecruitingNCT05702229

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participant...

10 locations(Los Angeles, Los Angeles, Baton Rouge)
240 participants
AstraZeneca
View Study Details
RecruitingNCT05789485

A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers

The purpose of this study is to find the level of aerobic exercise (AT) that is practical, is safe, and has positive effects on the body that may reduce the side effects of therapy. The study will als...

8 locations(Hartford, Basking Ridge, Middletown)
216 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNCT06173778

Semaglutide for Post-Smoking Cessation Weight Management

This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the contex...

2 locations(Austin, Houston)
197 participants
The University of Texas Health Science Center, Houston
View Study Details
RecruitingNCT06428409

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the can...

10 locations(Los Angeles, Aurora, Denver)
180 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNCT06628310

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is gi...

10 locations(Duarte, Irvine, Santa Monica)
180 participants
AbbVie
View Study Details
RecruitingNCT06722157

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan...

10 locations(Gilbert, Phoenix, Phoenix)
180 participants
Boehringer Ingelheim
View Study Details
RecruitingNCT06864169

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

Researchers are looking for new ways to treat certain types of advanced gastrointestinal (GI) cancers. The study medicine raludotatug deruxtecan (also called MK-5909, R-DXd, or DS-6000a) is a type of ...

10 locations(New Haven, Washington D.C., Miami Beach)
160 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNCT05271409

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the doubl...

10 locations(Birmingham, Scottsdale, Irvine)
152 participants
Hoffmann-La Roche
View Study Details
RecruitingNCT06709521

Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of m...

10 locations(Torrance, Torrance, Detroit)
150 participants
National Institute of Allergy and Infectious Diseases (NIAID)
View Study Details
RecruitingNCT03971409

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating pat...

10 locations(Birmingham, San Francisco, Washington D.C.)
150 participants
Laura Huppert, MD, BA
View Study Details
RecruitingNCT06038578

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with ...

10 locations(Duarte, Irvine, Santa Monica)
146 participants
Toray Industries, Inc
View Study Details
RecruitingNCT05645380

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

This study will assess if the presence of immune system cells in and around the tumor impacts tumor shrinkage in patients receiving neoadjuvant chemoimmunotherapy for triple-negative breast cancer....

7 locations(Fairway, Kansas City, Kansas City)
139 participants
University of Kansas Medical Center
View Study Details
RecruitingNCT06769048

A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 ...

10 locations(Gilbert, Phoenix, Phoenix)
138 participants
Boehringer Ingelheim
View Study Details
RecruitingNCT06469944

Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of sacituzumab tirumotecan with pembrolizumab and fluoropyrimidine chemotherapy for ...

10 locations(Tucson, Los Angeles, Louisville)
130 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNCT06596694

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the bod...

10 locations(Santa Monica, Aurora, Washington D.C.)
130 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNCT06632600

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

This study is to investigate the ability of LXE408 to reduce or remove the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without ...

10 locations(Boston, Houston, CABA)
130 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNCT06630234

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module...

10 locations(Scottsdale, La Jolla, Aurora)
120 participants
Deciphera Pharmaceuticals, LLC
View Study Details
RecruitingNCT06930625

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind per...

10 locations(Boston, St Louis, Las Vegas)
119 participants
Debiopharm International SA
View Study Details
RecruitingNCT03539822

Cabozantinib Plus Durvalumab with or Without Tremelimumab in Patients with Gastroesophageal Cancer and Other Gastrointestinal Malignancies

The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies ...

2 locations(Westwood, Pittsburgh)
117 participants
Anwaar Saeed
View Study Details
RecruitingNCT04660760

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

This phase II trial studies the effect of the combination of ramucirumab and trifluridine/tipiracil or paclitaxel in treating patients with previously treated gastric or gastroesophageal junction canc...

10 locations(Birmingham, Scottsdale, Tucson)
116 participants
Academic and Community Cancer Research United
View Study Details
RecruitingNCT04468061

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts ...

10 locations(Stamford, Chicago, Brewer)
110 participants
Dana-Farber Cancer Institute
View Study Details
RecruitingNCT06659549

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensit...

10 locations(Beverly Hills, Walnut Creek, Deerfield Beach)
110 participants
Galimedix Therapeutics Inc
View Study Details
RecruitingNCT06688539

E-cigarette Cessation in Adults Who Co-use Cannabis

The purpose of this study is to better understand tobacco outcomes using a commonly prescribed stop smoking medication (varenicline) and financial incentives for adults who also use cannabis. Varenicl...

3 locations(Charleston, Lancaster, Pickens)
105 participants
Medical University of South Carolina
View Study Details
RecruitingNCT07069712

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants ...

10 locations(Newark, Washington D.C., Fairway)
100 participants
AstraZeneca
View Study Details
RecruitingNCT06926920

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNB...

10 locations(Los Angeles, Atlanta, St Louis)
100 participants
Gilead Sciences
View Study Details
RecruitingNCT04725994

Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer

This is an open-label, Phase 1b/2a study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric ca...

10 locations(Los Angeles, Baton Rouge, Boston)
100 participants
Idience Co., Ltd.
View Study Details
RecruitingNCT02323399

Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV

The primary objective of this study is to evaluate the dose effect of Phenylephrine Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in the pediatric population...

10 locations(Wilmington, Washington D.C., Miami)
100 participants
West-Ward Pharmaceutical
View Study Details
RecruitingNCT05957367

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master pro...

9 locations(Los Angeles, Los Angeles, Miami)
94 participants
Deciphera Pharmaceuticals, LLC
View Study Details
RecruitingNCT06624670

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to closure of PG ulcers. This...

10 locations(Birmingham, Phoenix, Irvine)
90 participants
Boehringer Ingelheim
View Study Details
RecruitingNCT06445972

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, ...

10 locations(Tucson, Los Angeles, Louisville)
90 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNCT06856525

Dissolved Phase HXe-129 MRI: a Novel Biomarker to Quantify Pulmonary Pathology in Young Healthy E-cigarette Users

A two-center, longitudinal assessment of 40 electronic cigarette users and 40 healthy controls at the initial visit and a follow-up visit 12 months later. This study will determine the impact of elect...

2 locations(Durham, Charlottesville)
80 participants
Y. Michael Shim, MD
View Study Details
RecruitingNCT05319353

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

The main aim of this study is to find out the safety, tolerability and pharmacokinetics (PK) of maribavir for the treatment of CMV infection in children and teenagers after HSCT or SOT and to identify...

10 locations(Omaha, Cincinnati, Fort Worth)
80 participants
Takeda
View Study Details
RecruitingNCT05774665

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

The goal of this clinical trial is to determine the impact of omega-3 fatty acids on the production of anti-inflammatory effects and clinical improvement in people with depression who have not respond...

3 locations(Atlanta, Boston, Salt Lake City)
80 participants
Massachusetts General Hospital
View Study Details
RecruitingNCT03546686

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

The purpose of this study is to determine the impact of pre-operative cryoablation, and immune checkpoint inhibition (ICI) on on 3-year Event Free Survival (EFS), in women with residual hormone recept...

4 locations(Los Angeles, Columbus, Portland)
80 participants
University of Texas Southwestern Medical Center
View Study Details
RecruitingNCT07082543

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of GM1 gan...

10 locations(Oakland, Rochester, Fairfax)
75 participants
Azafaros A.G.
View Study Details
RecruitingNCT07160179

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. Geographic Atrophy (GA) is an advanced form o...

2 locations(Carmel, Dallas)
66 participants
AbbVie
View Study Details
RecruitingNCT06388083

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease...

10 locations(Phoenix, La Jolla, San Francisco)
60 participants
Belite Bio, Inc
View Study Details
RecruitingNCT05772546

Avatrombopag vs. Placebo for CIT in GI Malignancies

The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (...

4 locations(Miami, Boston, Portland)
60 participants
Hanny Al-Samkari, MD
View Study Details
RecruitingNCT03800693

2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers

This phase II trial studies how well giving oxaliplatin over 6 hours works in treating nerve damage in patients with gastrointestinal cancers. Oxaliplatin can cause side effects such as nerve damage t...

3 locations(Atlanta, Atlanta, Atlanta)
60 participants
Emory University
View Study Details
RecruitingNCT05004987

Aβ Dynamics in LLMD

This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depressio...

2 locations(New York, Orangeburg)
60 participants
NYU Langone Health
View Study Details
RecruitingNCT06712407

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have comple...

10 locations(Birmingham, Glendale, Orange)
60 participants
Calliditas Therapeutics AB
View Study Details
RecruitingNCT05626114

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related mac...

10 locations(Beverly Hills, Sacramento, San Francisco)
60 participants
Genentech, Inc.
View Study Details
RecruitingNCT04069273

Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Cohort 1 \[CLOSED\] Study treatment involves two segments: (1) Induction Immunotherapy segment with pembrolizumab monotherapy every 3 weeks until irRECIST PD and (2) Combination Therapy segment. Nab-p...

2 locations(Rochester, Milwaukee)
58 participants
Harry H Yoon
View Study Details
RecruitingNCT06942572

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

This Phase 1/2 study will evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection in subjects with Stargardt's Type 1 (STGD1). This...

5 locations(Aurora, Miami, Boston)
57 participants
Splice Bio
View Study Details
RecruitingNCT04545736

Oral Metformin for Treatment of ABCA4 Retinopathy

Background: ABCA4 retinopathy is a genetic disease in which the ABCA4 protein is absent or faulty. It can cause waste material to collect in the eye and may cause cells to die. The cell death can lea...

2 locations(Bethesda, Ann Arbor)
56 participants
National Eye Institute (NEI)
View Study Details
RecruitingNCT05956626

A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a 2:1 ratio to either ...

10 locations(Phoenix, Gainesville, Miami)
51 participants
Ocugen
View Study Details
RecruitingNCT06460298

ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

This is a Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an anti- αvβ3 Integrin Cytotoxin, in Combination with Gemcitabine in Patients with Metastatic Triple Negative Breast Cancer...

2 locations(Atlanta, Atlanta)
51 participants
ProDa BioTech, LLC
View Study Details
RecruitingNCT02583672

Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)

The purpose of this study is to measure levels of blood and brain chemicals related to oxidative stress and inflammation in healthy volunteers and individuals with Type 1 Gaucher disease (GD1) to see ...

2 locations(Minneapolis, New York)
50 participants
University of Minnesota
View Study Details
RecruitingNCT04434040

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulatin...

7 locations(San Francisco, Chicago, New Lenox)
40 participants
Dana-Farber Cancer Institute
View Study Details
RecruitingNCT06208748

SARC044: a Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST

This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib....

4 locations(Miami, Boston, Portland)
40 participants
Sarcoma Alliance for Research through Collaboration
View Study Details
RecruitingNCT04665037

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

This study aims to estimate the pharmacokinetics (PK) of posaconazole (POS, MK-5592) intravenous (IV) and powder for oral suspension (PFS) formulations in pediatric participants \<2 years of age with ...

10 locations(San Diego, Miami, Chicago)
40 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNCT03090165

Ribociclib and Bicalutamide in AR+ TNBC

This is an open label, multi-institutional, single arm phase II trial of ribociclib in combination with bicalutamide in advanced AR+ triple-negative breast cancer. No randomization or blinding is invo...

6 locations(Chicago, Lansing, New Brunswick)
37 participants
Kari Wisinski
View Study Details
RecruitingNCT06251973

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Participants will receive study treatment with agenT-797, botensilimab, balstilimab, ramucirumab, and paclitaxel. When participants start each agent will depend on how their disease is affecting them....

7 locations(Basking Ridge, Middletown, Montvale)
37 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNCT06116136

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch...

10 locations(Ocala, Noblesville, Houston)
32 participants
Servier Bio-Innovation LLC
View Study Details
RecruitingNCT06164587

Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy

This interventional study is a single-center, open label, 26-week study, designed to evaluate the safety and treatment efficacy of K8 in patients with geographic atrophy (GA) due to age-related macula...

9 locations(Loma Linda, Lexington, Portland)
30 participants
University of Kentucky
View Study Details
RecruitingNCT04308837

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation

Stomach cancer is the fifth most common digestive cancer and third main cause of death from cancer in the world. Modern management of Gastric cancer involves a multi-disciplinary approach involving su...

3 locations(New York, New York, New York)
29 participants
Icahn School of Medicine at Mount Sinai
View Study Details
RecruitingNCT04614558

Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance

The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with MGRS. Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of...

2 locations(Boston, New York)
27 participants
Columbia University
View Study Details
RecruitingNCT06557460

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

This is a Phase IIb randomized, clinical trial designed to assess the safety and efficacy of unilateral implantation of the CPCB-RPE1 implant in subjects with geographic atrophy involving the fovea. ...

5 locations(Beverly Hills, Huntington Beach, Los Angeles)
24 participants
Regenerative Patch Technologies, LLC
View Study Details
RecruitingNCT05831176

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

This study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participan...

10 locations(Phoenix, Apple Valley, La Jolla)
22 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingNCT06797518

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

A study to investigate the impact of iptacopan treatment on the underlying immunopathology in patients with IgAN by assessing changes in key clinical and molecular markers from baseline to 9 months. T...

4 locations(Buford, Chubbuck, Houston)
20 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNCT03266640

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovi...

9 locations(Los Angeles, San Francisco, Indianapolis)
20 participants
New York Medical College
View Study Details
RecruitingNCT05482516

Evaluating Novel Therapies in ctDNA Positive GI Cancers

This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic...

3 locations(Washington D.C., Washington D.C., Hackensack)
20 participants
Georgetown University
View Study Details

Top Cities for Geographic Atrophy Clinical Trials

Geographic Atrophy clinical trials are recruiting across 314 cities. Here are the cities with the most active studies:

About Geographic Atrophy

Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.

Clinical trials are advancing new treatments for geographic atrophy. Currently, 100 studies are recruiting a combined 27,038 participants across the United States. Research is being conducted by 71 organizations including Guerbet, Merck Sharp & Dohme LLC, Gilead Sciences and 68 others.

2026 Geographic Atrophy Research Landscape

As of March 2026, the geographic atrophy clinical trial landscape includes 100 actively recruiting studies across 314 cities in the United States. These studies are collectively seeking 27,038 participants, with an average enrollment target of 270 per study.

Research is being led by 71 different organizations, including Guerbet, Merck Sharp & Dohme LLC, Gilead Sciences, Regeneron Pharmaceuticals, AstraZeneca, and 66 others. The large number of sponsors reflects significant research interest and investment in geographic atrophy treatment advancement.

Geographically, geographic atrophy trials are most concentrated in Los Angeles, California (34 trials); Boston, Massachusetts (31 trials); New York, New York (22 trials); Phoenix, Arizona (16 trials); Miami, Florida (15 trials) and 7 other cities.

Featured Geographic Atrophy Studies

Highlighted recruiting studies for geographic atrophy, selected by enrollment size and research scope.

RecruitingNCT04373564

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x-ray, CT-scan or MRI investigations, doctors are using contrast media (a kind of dye) which can be given to patients by injection into a blood vessel or by mout...

Sponsor: Guerbet· 2,076 participants· 10 locations (Scottsdale, New Haven, Chicago, Peoria)
View full study details →
RecruitingNCT06393374

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare...

Sponsor: Merck Sharp & Dohme LLC· 1,530 participants· 10 locations (Mobile, Chandler, La Jolla, Los Alamitos)
View full study details →
RecruitingNCT05633654

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgica...

Sponsor: Gilead Sciences· 1,514 participants· 10 locations (Birmingham, Huntsville, Glendale, Phoenix)
View full study details →

Frequently Asked Questions About Geographic Atrophy Clinical Trials

Are there geographic atrophy clinical trials near me?

Yes, there are 100 geographic atrophy clinical trials currently recruiting across 314+ cities in the United States, including Los Angeles, California; Boston, Massachusetts; New York, New York. Browse the studies above to find one at a location convenient for you.

How do I join a geographic atrophy clinical trial?

To join a geographic atrophy clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.

Are geographic atrophy clinical trials free?

Yes, participation in geographic atrophy clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.

What types of geographic atrophy treatments are being studied?

Current geographic atrophy clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 71 research organizations.

Is it safe to participate in geographic atrophy clinical trials?

Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.

Data updated March 1, 2026 from ClinicalTrials.gov

About This Data

Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.

Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.

Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov